Kenvue is poised to make its mark as a great business with a new name. Abbott Labs has long-term upside in key healthcare end markets.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its financial results for the third quarter ending October 1, 2023, before market open on October 26, 2023.
Here are some of the tickers on my radar for Wednesday, Sept. 20, taken directly from my reporter's notebook.

2 Incredibly Cheap Dividend Stocks to Buy Now

08:30am, Wednesday, 20'th Sep 2023
High-quality dividend stocks tend to trade at enormous premiums. AT&T and Kenvue both trade at attractive multiples.
Kenvue faces significant challenges in the consumer healthcare sector, including sluggish growth, intense competition, and middle-tier brand positions. While the company has manageable debt levels, it

Kenvue: Interesting Times

12:19pm, Monday, 18'th Sep 2023
Kenvue's shares have fallen since its IPO due to high valuations and concerns about its growth composition. The company, a spin-off from Johnson & Johnson, is well-diversified with leading brands in c
Johnson & Johnson had spun off Kenvue, its consumer health division, to boost growth in its more profitable pharmaceutical and medical technology sectors. JNJ achieved a steady 3.3% revenue growth ove
American Tower has increased its payout every year since becoming a REIT. Brookfield Renewable has boosted its dividend by at least 5% annually over the past 12 years.
Kroger's reasonable valuation offers much more upside than your traditional grocer. Rollins' top-notch profitability highlights its incredible track record of tuck-in acquisitions.

Better Buy: J&J vs. Kenvue

05:30am, Wednesday, 13'th Sep 2023
Johnson & Johnson recently spun off its consumer health unit into a new company called Kenvue. The consumer health segment weighed on J&J's growth, but it could progress successfully as an independent
Kenvue Inc shares rose 2.5% in pre-market trading on Monday boosted by an upgrade by Deutsche Bank. The German investment bank has moved the firm, the consumer-health business spun-out of Johnson & Jo
You're familiar with its products, including Tylenol, Neutrogena, Listerine and Johnson's Baby Shampoo. Still, you may not be up to speed on Kenvue Inc. NYSE: KVUE and its status as a long-term divide
Kenvue, which was recently spun off from Johnson & Johnson, already pays an attractive dividend. The company supports that payout with a strong financial profile and durable business.

Is J&J a Buy After the Kenvue Separation?

06:00am, Wednesday, 06'th Sep 2023
J&J recently completed the spinoff of its consumer health business, letting go of star products that populate most of our medicine cabinets. But J&J's two other units, pharmaceuticals and medtech, act
Kenvue Incorporated is a leader in the consumer health industry with a large catalog of notable consumer brands. Kenvue has high brand recognition and market share in various sub-sectors of the health
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE